The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NHS-Galleri: Primary results from a randomised controlled trial to assess the clinical utility of a multi-cancer early detection (MCED) test in population screening.
 
Robert Swanton
Stock and Other Ownership Interests - Achilles Therapeutics; Bicycle Therapeutics; Epic Sciences; GRAIL; Relay Therapeutics; Saga Diagnostics
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Illumina; Lilly; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Pfizer; Roche; Roche/Genentech
Consulting or Advisory Role - Achilles Therapeutics; Amgen; AstraZeneca; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; GRAIL; Illumina; Medicxi; Medicxi; Metabomed; MSD; Novartis; Relay Therapeutics; Roche; Saga Diagnostics; Sarah Cannon Research Institute
Research Funding - Archer; AstraZeneca; BMS; Boehringer Ingelheim; Ono Pharmaceutical; Personalis; Pfizer; Roche
Patents, Royalties, Other Intellectual Property - Founder of Achilles Therapeutics: a biotechnology company funded by Syncona/Wellcome Trust to target clonal Neoantigens through vaccine and cell therapy approaches; Immune checkpoint intervention in cancer (PCT/EP2016/071471),; Method for determining whether an HLA allele is lost in a tumour (PCT/GB2018/052004); Method for identifying responders to cancer treatment (PCT/GB2018/)051912); Method for treating cancer (PCT/EP2016/059401).; Method for treating cancer based on identification of clonal neo-antigens (PCT/EP2016/059401); Method of detecting tumour recurrence (PCT/GB2017/053289); Method of identifying insertion/deletion mutation targets (PCT/GB2018/051892); Method of predicting survival rates for cancer patients (PCT/GB2020/050221); Methods for lung cancer detection (PCT/US2017/028013); PCT/EP2022/077987 – Methods and systems for tumour monitoring. (Inst); PCT/EP2023/059039 – Analysis of HLA alleles transcriptional deregulation. (Inst)
(OPTIONAL) Uncompensated Relationships - AstraZeneca (Inst)
 
Peter Johnson
No Relationships to Disclose
 
Thomas Round
Research Funding - GRAIL (Inst)
 
Jane Warwick
Research Funding - GRAIL (Inst)
 
Helen Jones
No Relationships to Disclose
 
Harpal Kumar
Employment - GRAIL
Leadership - GRAIL
Stock and Other Ownership Interests - GRAIL
 
Wei Liang
Employment - GRAIL
Stock and Other Ownership Interests - GRAIL
 
Rebecca Smittenaar
Employment - GRAIL Bio UK Ltd
Stock and Other Ownership Interests - GRAIL; Illumina
Travel, Accommodations, Expenses - GRAIL
 
Richard Neal
Consulting or Advisory Role - GRAIL Bio UK, Ltd; GRAIL Bio UK, Ltd (Inst)
Patents, Royalties, Other Intellectual Property - Named inventor of the PinPoint Test, and should this Test generate revenue then will have a revenue share through an agreement between PinPoint Data Science Limited, the University of Leeds, and Leeds Teaching Hospitals Trust
 
Peter Sasieni
Consulting or Advisory Role - GRAIL Bio UK, Ltd.; MEDIAN Technologies (Inst)
Research Funding - GlaxoSmithKline UK Ltd. (Inst); GRAIL Bio UK, Ltd. (Inst); Merck (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending related to HPV testing; Patent pending related to HPV testing (Inst)